IGSF1 deficiency: lessons from an extensive case series and recommendations for clinical management


on behalf of the IGSF1 clinical care group

1Department of Pediatrics, Leiden University Medical Center, Leiden, the Netherlands
2Department of Medicine, division of Endocrinology, Leiden University Medical Center, Leiden, the Netherlands
3Department of Pediatric Endocrinology, Emma Children’s Hospital, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands
4Department of Endocrinology and Metabolism, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands
5University of Cambridge Metabolic Research Laboratories, Wellcome Trust-Medical Research Council Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, United Kingdom
6Division of Endocrine and Metabolic Disorders, Instituto di Ricovery e Cura a Carettere Scientifico (IRCCS), Instituto Auxologico Italiano, Milan, Italy
7Department of Clinical Sciences and Community Health, Università degli Studi di Milano, Milan, Italy
8Department of Clinical Chemistry and Laboratory Medicine, Leiden University Medical Center, Leiden, the Netherlands
9Department of Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada
10Department of Clinical Genetics, Leiden University Medical Center, Leiden, the Netherlands

*authors contributed equally

IGSF1 clinical care group (affiliations on next page)


Abbreviated title: Clinical phenotype of IGSF1 deficiency

Key terms: IGSF1, central hypothyroidism, growth, puberty, adrenarche, obesity, clinical management

Word count: 3832

Number of tables: 4, figures: 2

Corresponding authors: Wilma Oostdijk (dpt. of Pediatrics, J6) and Nienke R. Biermasz (dpt. of Medicine, C7), Leiden University Medical Center, P/O 9600, 2300RC Leiden, Netherlands. Tel +31715262824/+31715263082, fax +31715248136, e-mail w.oostdijk@lumc.nl/n.r.biermasz@lumc.nl

Disclosure statement: the authors have nothing to disclose
11 Pediatric Endocrinology, Hackensack University Medical Center, Hackensack, New Jersey, United States of America
12 Department of Pediatrics, division of Pediatric Endocrinology, Erasmus MC, Rotterdam, the Netherlands
13 Centro de Investigaciones Endocrinológicas ‘Dr. César Bergadá’ (CEDIE), CONICET – FEI – División de Endocrinología, Hospital de Niños Ricardo Gutiérrez, Buenos Aires, Argentina
14 Department of Pediatrics, Beatrix Children’s Hospital, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands
15 Center for Medical Genetics, Ghent University Hospital, Ghent, Belgium
16 Department of Pediatrics, IWK Health Centre, Dalhousie University, Halifax, Nova Scotia, Canada
17 Department of Pediatrics, Slingeland Hospital, Doetinchem, the Netherlands
18 Developmental Endocrinology Research Group, Clinical and Molecular Genetics Unit, UCL Institute of Child Health, London, UK
19 Department of Pediatrics, Sint Franciscus Gasthuis, Rotterdam, the Netherlands
20 Department of Pediatrics, division of Pediatric Endocrinology, Ghent University Hospital, Ghent, Belgium
21 Department of Endocrinology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands
22 Department of Pediatrics, Gelre Hospitals, Apeldoorn, the Netherlands
23 Diabeter, National Centre for Pediatric and Adolescent Diabetes Care and Research, Rotterdam, the Netherlands
24 Department of Pediatrics, Rijnstate Hospital, Arnhem, the Netherlands
25 Genetic Service, Hackensack University Medical Center, Hackensack, New Jersey, United States of America
26 Pediatric Endocrinology Unit, Department of Translational Medical Sciences, University ‘Federico II’ of Naples, Naples, Italy
27 Department of Pediatric Endocrinology, Canisius-Wilhelmina Hospital, Nijmegen, the Netherlands
28 Department of Genetics, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands
Abstract

Context: Mutations in the immunoglobulin superfamily, member 1 (IGSF1) gene cause the X-linked IGSF1 deficiency syndrome consisting of central hypothyroidism, delayed pubertal testosterone rise, adult macroorchidism, variable prolactin deficiency, and occasionally transient partial GH deficiency. Since our first reports, we discovered 20 new families with 18 new pathogenic IGSF1 mutations.

Objective: We aimed to share data on the largest cohort of patients with IGSF1 deficiency to date and formulate recommendations for clinical management.

Methods: We collected clinical and biochemical characteristics of 69 male patients (35 children, 34 adults) and 56 female IGSF1 mutation carriers (3 children, 53 adults) from 30 unrelated families according to a standardized clinical protocol. At evaluation, boys were treated with levothyroxine in 89%, adult males in 44%, and females in 5% of cases.

Results: Additional symptoms in male patients included small thyroid gland volume (74%), high birth weight (25%), and large head circumference (20%). In general, the timing of pubertal testicular growth was normal or even premature, in contrast to a late rise in testosterone levels. Late adrenarche was observed in patients with prolactin deficiency, and adult DHEA concentrations were decreased in 40%. Hypocortisolism was observed in 6 of 28 evaluated newborns, although cortisol concentrations were normal later on. Waist circumference of male patients was increased in 60%, but blood lipids were normal. Female carriers showed low FT₄ and low-normal FT₃ in 18% and 60%, respectively, delayed age at menarche in 31%, mild prolactin deficiency in 22%, increased waist circumference in 57%, and a negative correlation between FT₄ concentrations and metabolic parameters.

Conclusion: IGSF1 deficiency represents the most common genetic cause of central hypothyroidism and is associated with multiple other characteristics. Based on these results, we provide recommendations for mutational analysis, endocrine work-up, and long-term care.
**Context**

We previously reported that loss-of-function mutations in the immunoglobulin superfamily, member 1 (IGSF1) gene in eleven families causes the X-linked IGSF1 deficiency syndrome (1). In males the phenotype is characterized by congenital central hypothyroidism, delayed testosterone rise in puberty but normal timing of testicular enlargement, adult macroorchidism, partial GH deficiency (GHD) in some patients during childhood (but with high-normal IGF-1 concentrations in adulthood) or lifelong prolactin deficiency, and overweight habitus (1-5). A minority of female heterozygous carriers exhibits central hypothyroidism (2).

*IGSF1* encodes a plasma membrane glycoprotein, and all described *IGSF1* mutations reported to date impair proper glycosylation and trafficking of the protein to the cell surface (1). Furthermore, *Igsf1*-deficient male mice show reduced serum TSH and T3 concentrations, decreased pituitary *Trhr* mRNA levels, and show larger body size and weight than wild-type mice (1). Yet, IGSF1’s specific local function remains enigmatic.

Within three years after the discovery of this syndrome, we have identified 20 new families carrying 18 new mutations. In order to provide a more precise description of the clinical characteristics of IGSF1 deficiency, a total of 69 male patients and 56 female carriers were invited for clinical characterization according to a defined uniform protocol. This allowed us to formulate recommendations for the clinical management of these patients.
Subjects and methods

Design

In this descriptive case series, we present data on the clinical and biochemical characteristics of pediatric and adult hemizygous male patients with a mutation in IGSF1, and of adult female heterozygous carriers. Data were collected according to a clinical protocol approved by the Medical Ethics Committee of the Leiden University Medical Center. All subjects gave written informed consent.

Subjects

All patients in whom our group identified a pathogenic mutation in IGSF1 were invited for additional investigations. We collected data on 35 boys (mean age 9.8 yr, range 0.2-17.6 yr), 34 male adults (48 yr, 18-88 yr), 3 girls (9.9, 12.2, and 16.4 yr), and 53 female adults (48 yr, 21-81 yr) from 30 unrelated families carrying IGSF1 mutations. The families were from the Netherlands (n=16), the UK (n=3), Italy (n=4), Morocco (n=2), and Argentina, Belgium, Canada, Israel, and the USA (n=1 each). Some characteristics of 24 males and 18 females from ten families within this cohort were previously reported (2), but were supplemented with additional data. Fifteen of 34 male adults were treated with levothyroxine at current evaluation, as were 31 of 35 male children, and 3 of 56 females. All others either chose not to be treated with levothyroxine in the absence of complaints, or had not yet started treatment after the detection of hypothyroidism in the course of our analysis of family members of probands. Pathogenicity of the variants was determined based on the presence of central hypothyroidism with proper phenotype-genotype segregation, and in silico and in vitro analysis of the mutated proteins, as previously described (1). For four variants, in vitro results appeared normal (see Supplemental Table 1 for a detailed description of the phenotypes of these variants as well as for those of previously published cases).
Parameters

Body fat percentage was evaluated with bioelectrical impedance analysis, using the Bodystat 1500MDD (Bodystat Limited, Isle of Man, British Isles). Testicular and thyroid gland size was measured in males using standard ultrasonographic imaging. Descriptions of age-specific reference intervals of anthropomorphic measurements, laboratory assays and reference intervals, and definition of hormone deficiencies are shown in the Supplemental Methods.

Statistics

Statistical analyses are described in the Supplemental Methods.
Results

Hypothalamic-pituitary-thyroid axis

All male patients showed central hypothyroidism (Supplemental Fig. 1A) and 59% were prolactin deficient (Table 1). The TSH peak 20 minutes after TRH stimulation was decreased in most neonates, and in the lower half of the reference range in most other cases (Supplemental Fig. 2). Many patients had a small thyroid gland; the volume was <2.5th percentile (7.7 mL) in 74% of cases, and “unmeasurably small” in two. Adult thyroid size (n=17) was smaller in patients on long-term levothyroxine replacement (median (interquartile range, IQR): 5.6 mL (1.4-6.7 mL), n=11) than in untreated patients (7.4 mL (6.4-14.8 mL), n=6) (P=0.021). The two patients with unmeasurable thyroid size were 68 and 88 yr old and started treatment with levothyroxine at the age of 6 yr and 30 yr, respectively.

Serum SHBG, an indicator of hypothyroidism in the liver, was significantly correlated with FT4 concentrations in treated and untreated adult patients (r=0.583, P=0.002), also after correction for body mass index (BMI) (corrected P=0.003).

Growth and development

Gestational age was normal, but birth weight was ≥0 SDS in 83% and ≥2.0 SDS in 25% of cases (Table 1). Psychomotor development was generally normal, although four received physical therapy for problems with gross motor skills described as ‘clumsiness’. Patients with sufficient available data showed a consistent, typical growth and pubertal development pattern of slow linear growth and delayed bone age during childhood, delayed pubertal testosterone production with subsequent delayed pubertal growth spurt and development of secondary sexual characteristics during adolescence, normal or early timing of the start of testicular growth, and normal adult height, as reported previously (2). Head circumference was slightly increased, being ≥0 SDS in 89% and ≥2 SDS in 20% (Supplemental Fig. 3).
In adulthood, IGF-1 concentrations tended to be high, being $\geq 0$ SDS in 87% and $\geq 2$ SDS in 20% of cases. On the contrary, pediatric IGF-1 concentrations were normal in all (Supplemental Fig. 4A).

Nine males (14%) had been diagnosed with partial GHD during childhood or adolescence. Seven of these are adults now, and six were retested after they reached adult height. The patient that was not retested in adulthood showed normal serum IGF-1 concentrations after cessation of rhGH therapy.

The six that were retested showed normal GH responses in all but one patient, in whom a peak GH of 1.24 ng/mL (reference range $>5$ ng/mL (6)) was observed during an insulin tolerance test (ITT) at 16 yr. He continued rhGH therapy and is now 19 years old (see Supplemental Methods for a description of his mutation, p.Val985Ala). Two other adults were first tested for GHD at 79 and 66 yrs of age and showed normal GH responses during ITT.

One patient did not show delayed bone age during childhood, but rather had advanced bone ages (+1.9 yr at ages 3.1 and 6.1 yr) and tall stature (2.3 SD higher than target height SDS). At age 10 yr his testicular volume was 1.7 SDS for age, while no pubic hair, testosterone or DHEAS production were observed. By that time, in the absence of a growth spurt, bone age was just 0.4 yr above chronological age, and he was obese (BMI 2.3 SDS). He was treated for central hypothyroidism from birth and IGF-1 was always around -1.0 SDS.

Puberty and gonadal function

GnRH testing was performed in nine pediatric patients aged 0.3-13.5 years yr old (Supplemental Table 2). One infant, tested at 3 months of age, showed an LH peak of 37.5 U/L and FSH peak of 22.8 U/L, consistent with the physiological minipuberty in infants (7). A boy of 6.6 yr old showed enlarged testes (3.4 SDS) and a borderline positive GnRH test (LH peak 5.2 U/L, Immulite immunoassay), but no other signs of pubertal development were observed in the years thereafter. Hormonal parameters were still pre-pubertal at 8 years of age (non-stimulated LH 0.3 U/L, FSH 4.3 U/L, testosterone $<0.7$ nmol/L). Five patients aged between 7.3 and 11.6 yr showed no activation of the hypothalamo-pituitary-gonadal (HPG) axis despite having enlarged (2.8-4.4 SDS) or normal testes for age (0.2-0.5 SDS) at palpation. Lastly, the first evidently positive GnRH tests were observed in two patients at
12.7 yr (LH peak 9.4 U/L) and 13.5 yr (LH peak 8.3 U/L, testes >25 mL). In all these patients, including those with pubertal GnRH tests, pubic hair and testosterone production (if these data were available) were absent, while testicular enlargement (≥4 mL) was observed in two of them as early as 2.6 yr and 2.8 yr. In most pediatric patients, ultrasonographic testicular volume was in the upper half of the reference range, but in 87% of adults it was ≥2.0 SDS (Supplemental Fig. 5). No testicular pathology was observed during ultrasonographic examinations, but two patients had suffered from testicular torsion at the age of 4 yr and 74 yr.

Fig. 1 displays (longitudinal) pediatric testosterone values from the entire cohort, showing a late start of testosterone rise in most. The GnRH test in thirteen late-pubertal or adult patients (range 16.7-66.4 yr) showed normal mean LH peaks of 26.3 U/L (SD 8.1 U/L) and mean FSH peaks of 15.5 U/L (SD 7.6 U/L). Mean testosterone concentrations in adults were below the reference range median in 90% of adult patients, as was LH in 93% (Table 2). FSH was normal, but relatively high compared to the low LH concentrations, resulting in an increased FSH/LH ratio. Inhibin B concentrations were normal, but the inhibin B/FSH ratio was below the reference range median in all adult patients (and decreased in 20%). Inhibin B concentrations in adults (n=20) were not significantly correlated to ultrasonographic testicular volume (P=0.677), and its correlations with FSH (P=0.060) and testosterone (P=0.057) were almost significant.

Two patients had been treated with testosterone during puberty (one and three years). Fertility was preserved in all evaluable individuals, except for one patient who was unable to reproduce and diagnosed with azoospermia, and was resistant to treatment with FSH and LH.

**Adrenal function**

Fig. 2 shows pediatric DHEAS plasma concentrations, revealing lower concentrations in those with prolactin deficiency (B=-1.357 nmol/L, P=0.001, corrected for age). Longitudinal data on DHEAS were available in four patients with prolactin deficiency, showing a late biochemical adrenarche (DHEAS >1.084 µmol/L (8)) at 13-16 yr. Adrenal steroids from 24-h urine were collected in five
patients aged 8.7, 8.8, 10.1, 12.4, and 13.0 yrs. Androgen metabolites (17-ketosteroids) were close to the lower limit of the reference range in all patients (Supplemental Fig. 6).

In adults, DHEA and DHEAS were below the reference range median in nearly all and decreased in 40% and 18%, respectively (Table 2). Androstenedione was generally normal, and no association between prolactin deficiency and adult adrenal steroid values was observed.

Cortisol concentrations were normal in all evaluated adult patients, and neither signs nor symptoms of hypocortisolism were observed. Hydrocortisone replacement was prescribed to only one 75 yr old patient, after showing an insufficient cortisol rise after administration of CRH (0.410 µmol/L, reference range >0.550 µmol/L), but a normal response to synthetic ACTH (0.840 µmol/L).

Six of the 28 (21%) patients whose adrenal axis was evaluated shortly after birth were diagnosed with hypocortisolism because of low random cortisol values or abnormal low-dose ACTH testing results. However, hydrocortisone replacement could be stopped within a few years in all, after the finding of normal random cortisol values or adequate cortisol responses to synthetic ACTH (0.610-0.700 µmol/L).

Metabolic parameters

Sixty-seven percent of male children were classified as overweight, and 21% as obese. Compared to the general population, BMI was >2.0 SDS in 37%. Waist circumference was increased (>2.0 SDS) in 57%, and fat percentage in 29% (Supplemental Table 3). Lipids were generally normal, although three children aged 0.8-3.5 yr showed increased total and LDL-cholesterol (cholesterol 2.7-3.6 SDS, LDL 2.7-4.5 SDS). All three were obese (BMI 2.2-3.1 SDS), and two were treated with levothyroxine. The untreated boy (0.8 yr old) also showed increased triglyceride concentrations (4.03 mmol/L, reference range 0.21-2.01 mmol/L), which improved after start of levothyroxine replacement at 1.3 yr (1.22 mmol/L). BMI-corrected leptin concentrations were slightly increased, as 84% showed concentrations ≥0.0 SDS and 21% ≥2.0 SDS. Fasting concentrations of glucose, insulin, and C-peptide were generally normal.
Increased BMI (>25 kg/m²) was observed in 73% of adult males (general Dutch population: 53.8%, \( P=0.017 \) (9)), but obesity (BMI >30.0 kg/m²) was only observed in 17% (general population: 14.1%, \( P=0.623 \)). Furthermore, waist circumference was increased (≥94.0 cm) in 60% and fat percentage in 20% (Supplemental Table 3). Lipid concentrations were generally normal, as were BMI-corrected leptin concentrations, glucose, and insulin, but C-peptide was increased in 40%. FT₄ concentrations were not significantly associated with any of these parameters (average \( P=0.509 \)).

Hypertension was diagnosed and treated in four patients (13%), type 2 diabetes mellitus in three (10%), and dyslipidemia in four (13%)(all >60.0 yr).

**Brain**

Four patients were diagnosed with attention deficit disorder, one with attention deficit hyperactivity disorder, one with social deficit hyperactivity disorder (10), and one showed deficits in attention and concentration at neuropsychological testing (13 yr old). All of these patients were younger than 25 yr, and four had been treated with psychostimulants. One other patient was diagnosed with a pervasive developmental disorder – not otherwise specified (PDD-NOS). In eight of 24 available MRI scans (six neonates), variable degrees of widening of the cerebrospinal fluid containing spaces were observed. The widening was located at the lateral and third ventricle in one, but in the others mostly in the peripheral spaces: around the cerebellum in one, frontal in three, and in the basal cistern in three. In one of these six patients, however, a frontoparietal hygroma was diagnosed and treated with a ventriculoperitoneal shunt after being evaluated for macrocephaly at six months old (head circumference 5.1 SDS). In the remaining fourteen patients neuro-imaging showed no abnormalities, besides hypoplasia of the corpus callosum in one case. No signs of cognitive impairment were observed.

**Female carriers**

In female heterozygous carriers, FT₄ was below the lower limit in 18%, and in the lower tertile of the reference range in 60% (Supplemental Fig. 1B). IGF-1 concentrations were \( \geq 2.0 \) SDS in 31%
(mean±SD: 1.1±1.7, n=42, Supplemental Fig. 4B) and mild prolactin deficiency was present in 22%, although no one reported a history of problems with lactation. TRH tests were performed in six adult females (three of whom had decreased basal FT$_4$), showing normal or exaggerated TSH peaks at 20 minutes (8.0-32.4 mU/L; reference range: >2.8 mU/L). Five of ten female carriers with decreased FT$_4$ started treatment with levothyroxine after initial investigations, and all reported improvement of energy levels. Eight adult females underwent thyroid ultrasonography, showing a thyroid volume below the reference range median (<10.0 mL) in seven (two were on levothyroxine replacement) and <2.5th percentile (<4.8 mL) in two (untreated). No evident relation with X-chromosome inactivation was observed, as those with skewed inactivation (5 of 29 informative test results) showed central hypothyroidism in only two without hypoprolactinemia. Age at menarche was delayed (>14.5 years (11)) in 15 of 48 females (31%) with available data. No correlation was found between FT$_4$ concentrations and age at menarche, and no fertility issues were reported. Cortisol was normal in all females (0.372±0.202 µmol/L; reference range 0.100-0.600 µmol/L).

Females showed a metabolic profile similar to males, with increased BMI in 55%, waist circumference in 57%, and fat percentage in 36% (Supplemental Table 3). Triglycerides, cholesterol, HDL, and BMI-corrected leptin were generally normal, but LDL was increased in 37%. Glucose, insulin, and C-peptide were generally normal. FT$_4$ concentrations were significantly correlated to waist circumference ($r=0.345$, $P=0.022$), triglyceride concentrations ($r=0.375$, $P=0.010$), and fasting glucose ($r=0.409$, $P=0.005$). One adult female was treated for hypercholesterolemia (63.9 yr), one for hypertension (62.2 yr), and none for diabetes mellitus.

For all characteristics of IGSF1 deficiency in males and females, no clear genotype-phenotype relation was observed, and signs and symptoms varied within families with the same mutation.
Discussion

The results of this case series of patients with the X-linked IGSF1 deficiency syndrome, the largest to date, reveal new symptoms and expand the information on previously reported symptoms. Despite having been discovered only recently, this syndrome already encompasses more unique mutations and patients than all other known genetic causes of isolated central hypothyroidism combined (TSHB (12-16) and TRHR (17,18)). An overview of the clinical features of IGSF1 deficiency is presented in Table 3, and recommendations for genetic evaluation and clinical management are provided in Table 4.

Central hypothyroidism and growth

Central hypothyroidism remains the key feature of IGSF1 deficiency, being present in all male cases. As central hypothyroidism was previously also proposed to be the key feature (1,2), and most new index cases were discovered based on this sign, its prevalence might be subject to selection bias. Nevertheless, all non-index cases also showed central hypothyroidism. Growth velocity was usually decreased and bone age delayed (2), and partial GHD was diagnosed in 14%. We therefore advise stringent follow-up of growth, supplemented by IGF-1 concentrations, bone age determination, and (primed) GH stimulation tests in case of growth failure. As GHD proved transient in most, but not all, patients treated with rhGH, GH stimulation tests should be repeated after reaching adult height.

Pubertal development and adult gonadal functioning

The pubertal rise in testosterone was often delayed, in contrast to a normal or even advanced start of testicular growth. The mechanism of this disharmonious pubertal development as well as the adult macroorchidism has not yet been elucidated. However, current data in the limited number of pubertal patients studied suggest a combination of both central and testicular causes. A central cause of the delayed testosterone rise is supported by slightly delayed activation of the hypothalamic-pituitary-
gonadal axis in GnRH stimulation tests, with relatively high FSH values that could contribute to
testicular enlargement (15;16). Additionally, testicular function might be altered through decreased
penetrance of thyroid hormone in the testis, resulting in early and prolonged proliferation of Sertoli
cells (causing macroorchidism) and decreased receptivity of Leydig cells to LH (causing delayed
testosterone rise) (15;16). The normal inhibin B concentrations (a marker of Sertoli cell number and
stimulated by FSH) despite macroorchidism and relatively high FSH concentrations might indicate
decreased Sertoli cell function or decreased negative feedback of inhibin B at the pituitary level,
although previous investigations reported no evidence for the latter (19). We advise to monitor
pubertal development annually using height, pubic hair staging, testicular volume, and testosterone
concentrations (when testes reach ≥4 mL). Treatment with testosterone should be considered when
pubic hair stage 1 and/or prepubertal testosterone concentrations are observed at the age of 14.0 yr or
greater. We discourage screening for IGSF1 mutations in patients with delayed puberty and a normal
thyroid function (20).

Neonatal hypocortisolism

Although hypocortisolism was diagnosed in 21% of newborns (available data in 28 males [41%]), this
condition proved transient within a few years in all. In some newborns hypocortisolism was only
based on randomly measured cortisol concentrations, which may have resulted in overestimation of its
prevalence. Because of these two points, plus the absence of IGSF1 expression in corticotroph cells of
the rat pituitary gland (21), we consider the chance that the adrenal axis is perturbed in IGSF1
deficiency remote. Nevertheless, we cannot rule out true neonatal hypocortisolism, and given the
potentially dangerous nature of this condition we suggest dynamic adrenal axis testing in all newborns
with central hypothyroidism. If adrenal insufficiency is diagnosed, hydrocortisone treatment should be
initiated before the start of levothyroxine replacement because of the risk of initiating symptomatic
adrenal insufficiency (22). Consequently, if dynamic testing cannot be performed, prophylactic
glucocorticoid replacement should be considered just like in other causes of central hypothyroidism
(23).
Brain

Variable degrees of widening of the liquor containing spaces were observed in 8 of 24 MRI scans. However, most findings were in neonates in whom this can be a variation of normal development known as benign external hydrocephalus (BEH) (24). BEH is the most prevalent cause of (familial) macrocephaly and usually resolves by the age of 2 years although macrocephaly may persist. Increased head circumference was indeed observed in 20% of patients, and has also been reported in other causes of congenital hypothyroidism (25) and in patients with resistance to thyroid hormone due to a mutation in the THRA gene (26). Although one patient was treated for frontoparietal hygroma, we do not believe that these results warrant standard cerebral imaging in patients with IGSF1 deficiency and a normal head circumference, given the low prevalence and benign character of BEH. In addition, we previously reported mild but consistent deficits in attentional control (27), and seven patients (10.1%) were diagnosed with disorders related to attention (pediatric population prevalence of ADHD: 7.2% (28)). Treating physicians should be aware of these potential problems. Also, problems with gross motor skills should be recognized early, as four patients benefited from physical therapy.

Additional symptoms

First, we observed (very) small thyroid glands, especially in patients with suppressed TSH. This finding likely results from decreased TSH signaling (29-33), and warrants caution when patients on long-term treatment consider stopping levothyroxine replacement and in pregnant heterozygous females. Second, we observed increased birth weight in one-third of patients, in accordance with two of six Japanese cases of IGSF1 deficiency (5) as well as with other causes of congenital hypothyroidism (34). Third, a late adrenarche was observed in patients with prolactin deficiency, although data were limited. Prolactin receptors are highly expressed in the adrenal gland and synergize with ACTH to augment adrenal androgen secretion (35-37). Furthermore, experimental lowering of prolactin concentrations decreases DHEAS, whereas DHEAS is elevated in hyperprolactinemia (38,39). Prolactin deficiency may therefore be considered as the main cause of
late adrenarche in IGSF1-deficient patients. An association between adrenal steroids and prolactin concentrations was absent in adults.

**Treatment**

The degree of hypothyroidism varied, and for all patients it was unknown to what extent FT$_4$ concentrations were below individual and optimal set-points, and how long-term congenital hypothyroidism may have affected this set-point. There are, however, several arguments in favor of treatment. We observed prolonged jaundice, growth delay, obesity, and sometimes dyslipidemia in untreated children who later responded well to the initiation of treatment (1). In male adults, BMI-corrected SHBG concentrations (a marker of liver hypothyroidism) were significantly correlated to free T4 concentrations, implying suboptimal thyroid hormone exposure in untreated individuals. We also observed higher waist circumference, triglycerides, and glucose in females with lower FT$_4$ concentrations. Male and female adults who started treatment after diagnosis reported major improvements in energy levels, as previously described in other hidden forms of central hypothyroidism (23), although long-term results in our patients are unavailable. On the other hand, untreated adults were generally well-functioning, well-educated, of normal height, rarely showed dyslipidemia or cardiovascular disease, and were not more obese than their treated peers. Nevertheless, we advise treatment of all children with levothyroxine, commencement of a trial course in all male adults and in female adults with low (-normal) thyroxine concentrations, and re-assessment of FT$_4$ concentrations in females before and during pregnancy.

**Genetic evaluation**

We advise genetic evaluation of all patients with central hypothyroidism of unknown cause for IGSF1 mutations, especially when accompanied by an X-linked inheritance pattern, prolactin or GH deficiency, disharmonious pubertal development, macroorchidism, or delayed adrenarche. As asymptomatic adult carriers are likely to benefit from treatment with levothyroxine, family members
should be evaluated based on the X-linked inheritance pattern. All children of female carriers (and female children of male patients) should be screened at birth with TSH and T4.

In conclusion, this study describes the phenotype of the X-linked IGSF1 deficiency syndrome in the largest cohort known to date. The results include new symptoms, as well as an expansion of the information on known symptoms, allowing us to formulate recommendations for clinical management.
Acknowledgements

The authors acknowledge the efforts of P. Beck-Pecco, I. Campi, K. Chatterjee, E.P. van der Kleij – Corssmit, S.E. Hannema, and L. Klieverik for conceptualization of the study. We furthermore thank S. Dyack, E.F. Gevers, M.M. van Haelst, C. Noordam, M. Pekelharing-Berghuis, J. Smit, A. Vandersteen, and A.H. van der Vlugt for sharing patient data, and dr. M.C. Kruit for neuroradiological analysis of cerebral imaging. DJB was supported by operating grant MOP-133557 from the Canadian Institutes for Health Research, MOT by a graduate research award from the Natural Sciences and Engineering Research Council of Canada, and NS by the Wellcome Trust (100585/Z/12/Z) and the National Institute for Health Research Biomedical Research Centre Cambridge, United Kingdom.
References


30. Fast S, Nielsen VE, Bonnema SJ, Hegedus L. Dose-dependent acute effects of recombinant human TSH (rhTSH) on thyroid size and function: comparison of 0.1, 0.3 and 0.9 mg of rhTSH. Clin Endocrinol (Oxf) 2010; 72:411-416


Table 1. Basic clinical characteristics of the male study population

<table>
<thead>
<tr>
<th></th>
<th>N</th>
<th>Children</th>
<th>N</th>
<th>Adults</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gestational age at birth (wk)</td>
<td>26</td>
<td>40.6 (40.0-41.6)</td>
<td>15</td>
<td>41.0 (39.0-43.0)</td>
</tr>
<tr>
<td>Birth weight (SDS)</td>
<td>31</td>
<td>0.9 (0.2-1.7)*</td>
<td>21</td>
<td>1.2 (0.7-2.4)*</td>
</tr>
<tr>
<td>Head circumference (SDS)</td>
<td>26</td>
<td>0.9 (0.5-1.2)*</td>
<td>25</td>
<td>1.2 (0.8-2.1)*</td>
</tr>
<tr>
<td>Height (SDS)</td>
<td>21</td>
<td>-0.6 (-1.4- -0.2)* f</td>
<td>30</td>
<td>-0.2 (-1.1-0.3)</td>
</tr>
<tr>
<td>Thyroid volume &lt;P50 / &lt;P2.5</td>
<td>21</td>
<td>95% / 67%</td>
<td>17</td>
<td>88% / 82%</td>
</tr>
<tr>
<td>TSH at diagnosis (mU/L)a</td>
<td>32</td>
<td>2.15 (1.53-3.28)</td>
<td>28</td>
<td>1.70 (1.20-2.76)</td>
</tr>
<tr>
<td>Free T4 at diagnosis (pmol/L)b</td>
<td>32</td>
<td>9.1 (8.1-9.6)*</td>
<td>28</td>
<td>9.0 (8.5-9.4)*</td>
</tr>
<tr>
<td>Central hypothyroidism</td>
<td>35</td>
<td>100%</td>
<td>34</td>
<td>100%</td>
</tr>
<tr>
<td>Prolactin deficiency</td>
<td>34</td>
<td>62%</td>
<td>31</td>
<td>55%</td>
</tr>
<tr>
<td>(transient) GH deficiency</td>
<td>35</td>
<td>11%</td>
<td>34</td>
<td>15%g</td>
</tr>
<tr>
<td>IGF-1 (SDSc)</td>
<td>28</td>
<td>-0.6 (-1.0-0.4)</td>
<td>30</td>
<td>1.1 (0.2-1.7)*</td>
</tr>
<tr>
<td>Cortisol (µmol/L)d</td>
<td>32</td>
<td>0.268 (0.213-0.347)</td>
<td>26</td>
<td>0.381 (0.317-0.464)</td>
</tr>
<tr>
<td>Adult testis volume (SDS)</td>
<td>-</td>
<td>-</td>
<td>23</td>
<td>3.5 (2.4-5.1)*</td>
</tr>
<tr>
<td>Adult thyroid volume (mL)e</td>
<td>-</td>
<td>-</td>
<td>17</td>
<td>6.5 (4.6-7.1)*</td>
</tr>
</tbody>
</table>

Data are presented as median (interquartile range). aTSH normal range: 0.30-4.80 mU/L. bNormal ranges vary with age and assay. See Supplemental Fig. 1 for free T4 at diagnosis relative to reference range. cIn patients not treated with rhGH. dEarly morning fasting withdrawal. In-house reference values for cortisol are 0.100-0.600 µmol/L. eReference values in adult men: 19.1 mL (P50) and 7.7 mL (P2.5) (40). fOnly Dutch children. gIn these adults, GH deficiency had been transiently present only during childhood and adolescence, except for one patient of 19 years old. SDS, standard deviation score. *Different from population median at P < 0.05.
Table 2. Adrenal and gonadal functioning in male adults

<table>
<thead>
<tr>
<th></th>
<th>N</th>
<th>Reference range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (y)</td>
<td>32</td>
<td>30.9 (23.4-66.3)</td>
</tr>
<tr>
<td>LH (U/L)</td>
<td>29</td>
<td>3.3 ± 1.5*</td>
</tr>
<tr>
<td>FSH (U/L)</td>
<td>29</td>
<td>8.2 ± 6.5</td>
</tr>
<tr>
<td>FSH / LH ratio</td>
<td>29</td>
<td>2.2 (1.8-2.7)*</td>
</tr>
<tr>
<td>Testosterone (nmol/L)</td>
<td>31</td>
<td>14.0 ± 5.0*</td>
</tr>
<tr>
<td>SHBG (nmol/L)</td>
<td>25</td>
<td>29.6 ± 15.5*</td>
</tr>
<tr>
<td>Inhibin B (ng/L)</td>
<td>20</td>
<td>253.6 ± 111.0</td>
</tr>
<tr>
<td>Inhibin B / FSH ratio</td>
<td>20</td>
<td>31.5 (17.2-55.6)*</td>
</tr>
<tr>
<td>AMH (µg/L)</td>
<td>21</td>
<td>7.0 (2.7-13.0)</td>
</tr>
<tr>
<td>Androstenedione (nmol/L)</td>
<td>24</td>
<td>6.3 (3.4-9.0)</td>
</tr>
<tr>
<td>DHEA (nmol/L)</td>
<td>20</td>
<td>9.7 (5.7-19.3)*</td>
</tr>
<tr>
<td>DHEAS (µmol/L)</td>
<td>22</td>
<td>3.3 (1.3-4.9)*</td>
</tr>
</tbody>
</table>

Data are presented as median (interquartile range) or mean ± SD. AMH, Anti-Müllerian hormone; DHEA(S), dehydroepiandrosterone (sulphate). *Different from population median at \( P < 0.05 \).
**Table 3. Clinical features of the X-linked IGSF1 deficiency syndrome**

<table>
<thead>
<tr>
<th>Hemizygous males</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Central hypothyroidism</td>
<td>100%</td>
</tr>
<tr>
<td>Low-normal testosterone concentrations in adulthood</td>
<td>88%</td>
</tr>
<tr>
<td>Adult macroorchidism</td>
<td>88%</td>
</tr>
<tr>
<td>Delayed pubertal testosterone rise, early/normal timing of testicular growth</td>
<td>75%</td>
</tr>
<tr>
<td>Mild problems with attentional control</td>
<td>75%</td>
</tr>
<tr>
<td>Small thyroid gland</td>
<td>74%</td>
</tr>
<tr>
<td>Increased waist circumference in adults</td>
<td>59%</td>
</tr>
<tr>
<td>Prolactin deficiency</td>
<td>61%</td>
</tr>
<tr>
<td>Late biochemical adrenarche</td>
<td>50%</td>
</tr>
<tr>
<td>Increased waist circumference in children</td>
<td>57%</td>
</tr>
<tr>
<td>Decreased DHEA in adulthood</td>
<td>40%</td>
</tr>
<tr>
<td>Benign external hydrocephalus</td>
<td>33%</td>
</tr>
<tr>
<td>Increased birth weight</td>
<td>26%</td>
</tr>
<tr>
<td>Hypocortisolism in infancy</td>
<td>21%</td>
</tr>
<tr>
<td>Increased IGF-1 concentrations in adulthood</td>
<td>20%</td>
</tr>
<tr>
<td>Increased head circumference</td>
<td>20%</td>
</tr>
<tr>
<td>Growth hormone deficiency in childhood</td>
<td>16%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Heterozygous females</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Delayed age at menarche</td>
<td>31%</td>
</tr>
<tr>
<td>Prolactin deficiency (non-symptomatic)</td>
<td>22%</td>
</tr>
<tr>
<td>Central hypothyroidism</td>
<td>18%</td>
</tr>
</tbody>
</table>

Based on reported data from current study and (1,3-5). *Estimated based on limited data*
### Table 4. Recommendations for clinical management of IGSF1 deficiency

**Indications for mutational analysis of IGSF1**

Central hypothyroidism of unknown cause, especially when accompanied by:
- X-linked inheritance pattern
- Deficiency of prolactin or GH
- Disharmonious pubertal development, macroorchidism, or delayed adrenarche

Screen appropriate family members after a mutation is discovered.

<table>
<thead>
<tr>
<th>Diagnosis and follow-up</th>
<th>Children</th>
<th>Adults</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Diagnosis Follow-up</td>
<td>Transition</td>
</tr>
<tr>
<td><strong>Males</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>History, physical examination</td>
<td>X(^a)</td>
<td>X</td>
</tr>
<tr>
<td>FT(_a), TSH</td>
<td>X</td>
<td>X(^c)</td>
</tr>
<tr>
<td>Testosterone</td>
<td>X annual if testes ≥4 mL</td>
<td>X</td>
</tr>
<tr>
<td>Prolactin</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Dynamic adrenal axis testing</td>
<td>X(^d)</td>
<td>X</td>
</tr>
<tr>
<td>Cortisol (early a.m.)</td>
<td>X(^e)</td>
<td>X</td>
</tr>
<tr>
<td>IGF-1</td>
<td>X (^c)</td>
<td>X</td>
</tr>
<tr>
<td>Cholesterol, TG, HDL, LDL, glucose</td>
<td>X (^c)</td>
<td>X</td>
</tr>
<tr>
<td><em>If growth failure or low IGF-1:</em></td>
<td>X (^f)</td>
<td></td>
</tr>
<tr>
<td>(Primed) GH stimulation test, hand X-ray</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td><strong>Females</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>History, physical examination</td>
<td>X(^a)</td>
<td></td>
</tr>
<tr>
<td>FT(_a), TSH</td>
<td>X</td>
<td>X(^g)</td>
</tr>
<tr>
<td>Cholesterol, TG, HDL, LDL, glucose</td>
<td>X (^c)</td>
<td>X</td>
</tr>
<tr>
<td><strong>Treatment</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Levothyroxine</td>
<td>In all male children. Trial course in male adults, and in females with decreased free T(_4) or low-normal free T(_4) in combination with features suggestive of tissue hypothyroidism.</td>
<td></td>
</tr>
<tr>
<td>Hydrocortisone</td>
<td>In neonates with impaired cortisol response in low-dose ACTH test (&lt;0.550 µmol/L). Re-evaluate after one year</td>
<td></td>
</tr>
<tr>
<td>rhGH</td>
<td>In case of &gt;1.0 SD deviation of growth, height &lt;−2 SD, or low growth velocity, and impaired GH response in (primed) GH stimulation test</td>
<td></td>
</tr>
<tr>
<td>Testosterone</td>
<td>In case of a delay in pubertal development in males (pubic hair stage 1 and/or prepubertal testosterone at 14.0 yr)</td>
<td></td>
</tr>
</tbody>
</table>

\(^a\)Height, weight, head circumference, pubic hair, testicular volume, heart rate. Periodic evaluation at the discretion of the treating physician.

\(^b\)BMI, waist circumference, signs and symptoms of hypothyroidism and, if treated with levothyroxine, of hyperthyroidism. Periodic evaluation at the discretion of the treating physician.

\(^c\)Follow-up at the discretion of the treating physician.

\(^d\)Dynamic testing may be preceded by randomly measured plasma or serum cortisol concentrations. Sufficiently high concentrations make central adrenal insufficiency unlikely. However, low concentrations do not prove adrenal insufficiency. In case of a low random cortisol concentration in a neonate we suggest to perform a low-dose ACTH test. If abnormal (cortisol response <0.550 µmol/L), then treat with hydrocortisone. Re-evaluate after one year.

\(^e\)Sufficiently high concentrations make central adrenal insufficiency unlikely. A low concentration warrants dynamic adrenal axis testing.

\(^f\)Repeat GH stimulation test at transition in patients treated for GH deficiency.

\(^g\)Age 0-3 yr: at least yearly, also if hypothyroidism is absent. Age 4-18 yr: at discretion of treating physician.

\(^h\)Preconception and during pregnancy. If hypothyroid, follow-up at the discretion of the treating physician.
TG, triglycerides; LT4, levothyroxine.

**Figure legends**

**Figure 1.** Testosterone concentrations in male patients. Lines represent longitudinal data and dots individual patients. Reference intervals were derived from Andersson *et al.* (41).

**Figure 2.** DHEAS concentrations in male patients around the age of biochemical adrenarche (1.084 µmol/L, dotted line). Lines represent longitudinal data, and the larger diamonds/dots are data from individual patients. Smoothed reference intervals were derived from Elmlinger *et al.* (42).